Oxidative cues as theranostic switches for the ROS-responsive Nanotheranostics in oxidative stress-driven diseases

Read full text
Authors: Shameer Pillarisetti, Rosanna Alfieri, Paola Palumbo, Bruno Filipe Carmelino Cardoso Sarmento, Christian Celia, Massimo Fresta
Cited by: 1
References: 51

Abstract

Nanotheranostics (NTs) are nanoscale systems that combine disease diagnosis and targeted therapy. They often respond to specific signals, such as reactive oxygen species (ROS). These platforms leverage elevated ROS levels associated with diseases, such as neurodegeneration, cancer, cardiovascular disorders, and inflammation, to control drug release and support targeted imaging. In this review, we have described the different roles of ROS in neurological disorders (Alzheimer's disease), cancer, cardiovascular diseases (including atherosclerosis and myocardial infarction), and joint inflammation (arthritis). We also discuss the relative applications of ROS-responsive NTs. By integrating diagnosis and treatment, ROS-responsive NTs can improve treatment outcomes, reduce side effects, and help clinicians track disease progression and therapeutic response in real time. Advanced NTs are sensitive to additional triggers, such as pH, thermal, and hypoxic conditions. This sensitivity improves accuracy and outcomes for ROS-driven diseases. This strategy shows promise for precision medicine by using multifunctional, stimulus-activated nanomedicines to treat diseases driven by oxidative stress. This review summarizes recent advances, focusing on nanomaterial composition and chemistry for ROS response or scavenging to improve diagnosis and treatment. Finally, we explore current advances and perspectives on ROS-based NTs across ROS-driven diseases.

Fields of Study & Subjects

Neutrophil Myeloperoxidase and Oxidative Mechanisms Advanced Nanomaterials in Catalysis Redox biology and oxidative stress

Publication details

Journal / source
Journal of Controlled Release
Publisher
Elsevier BV
Volume
394
Pages
114933–114933
Publication date
15 April 2026
Language
EN